Relief Therapeutics

Welcome to

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Relief is a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis.

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma

17 January 2023 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

20 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Issuance of Shares from Authorized Capital

13 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Executive Leadership Team Changes

8 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

16 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

14 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

8 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

7 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Latest News

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

Relief Therapeutics Announces Executive Leadership Team Changes

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

Company

Pipeline

Investor Relations

News and Events